Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying ...

5, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) ...

Merck Sharp & Dohme LLC has identified plasma kallikrein (KLKB1) Inhibitors reported to be useful for the treatment of diabetic retinopathy, retinal vein occlusion, hereditary angioedema, diabetes, ...

Merck & Company Inc (NYSE:MRK) was up 10% YTD as of Friday, August 30 ’24, but had been up as much as 21% at various times through the 2nd quarter, but the Q2 ’24 earnings release put a big ...

Sharp HealthCare and Palomar Health jointly announced Wednesday that they will collaborate on patient care in North County, working together to “establish programs across clinical service lines ...

Aug 29 (Reuters) - Merck (MRK.N), opens new tab has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday ...

Households may be falling out of love with smart meters, as the latest Government figures show another decline in installations. Smart meters can communicate with energy firms in real time ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.